Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786247 | 1.00 | ABCB1 (0.47) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL29786239 | 1.00 | ABCB1 (0.47) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL2683613 | 1.00 | ABCB1 (0.47) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL2683263 | 1.00 | ABCB1 (0.47) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL16034785 | 0.98 | ABCB1 (0.45) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL13983597 | 0.93 | ABCB1 (0.41) | ABCB1CYP3A4HDAC3HDAC1HDAC2 | |
| SCHEMBL21867268 | 0.92 | ABCB1 (0.42) | ABCB1CYP3A4HDAC1 | |
| SCHEMBL19946435 | 0.89 | ABCB1 (0.60) | ABCB1CYP3A4 | |
| SCHEMBL4283145 | 0.89 | ABCB1 (0.60) | ABCB1CYP3A4 | |
| SCHEMBL2682193 | 0.89 | ABCB1 (0.60) | ABCB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | claimed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2013036574-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-2167458-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153801-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885HDAC3 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.